Azacitidine: In myelodysplastic syndromes

Drugs

Volumn 65, Issue 13, 2005, Pages 1781-1789

  Siddiqui, M Asif A ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYTOSINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; AREA UNDER THE CURVE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DISEASE SEVERITY; DNA METHYLATION; DNA REPLICATION; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG STRUCTURE; DRUG TOLERABILITY; ECCHYMOSIS; ERYTHEMA; FATIGUE; FEVER; GRANULOCYTOPENIA; HUMAN; INFECTION; INJECTION SITE REACTION; LEUKOPENIA; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; PROGNOSIS; QUALITY OF LIFE; RECIPIENT; REVIEW; THROMBOCYTOPENIA; TOXICITY; TRANSFUSION; TREATMENT FAILURE; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS, PHASE III; HUMANS; MYELODYSPLASTIC SYNDROMES; QUALITY OF LIFE;

EID: 24344435916     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565130-00004     Document Type: Review

References (25)

1. Faderl S, Kantarjian HM. Novel therapies for myelodysplastic syndromes. Cancer 2004; 101 (2): 226-41
2. Silverman LR. Neoplasms of the hematopoietic system: myelodysplastic syndrome. In: Bast RC, Kufe DW, Pollock RE, et al, editors. Holland-Frei cancer medicine e.5. 5th ed. Ontario (BC): B.C. Decker Inc., 2000
3. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51 (2): 189-99
4. Silverman LR. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 2001; 6 Suppl. 5: 8-14
5. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17 (12): 3835-49
6. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89 (6): 2079-88
7. National Comprehensive Cancer Network (NCCN) myelodysplastic syndromes panel. NCCN clinical practice guidelines in oncology: myelodysplastic syndromes: version 1.2005 [online]. Available from URL: http://www.nccn.org [Accessed 2005 Aug 1]
8. Glover AB, Leyland-Jones B. Biochemistry of azacitidine: a review. Cancer Treat Rep 1987; 71 (10): 959-64
9. Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002 Dec; 87 (12): 1324-41
10. Dhodapkar M, Grill J, Lust JA. Abnormal regional hypermethycycles lation of the calcitonin gene in myelodysplastic syndromes. Leuk Res 1995; 19 (10): 719-26
11. INK4b gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91 (8): 2985-90
12. Murakami T, Li X, Gong J, et al. Induction of apoptosis by 5-azacytidine: drug concentration-dependent differences in cell cycle specificity. Cancer Res 1995 Jul 15; 55 (14): 3093-8
13. Lopez-Karpovitch X, Barrales-Benitez O, Flores M, et al. Effect of azacytidine in the release of leukemia inhibitory factor, oncostatin M, interleukin (IL)-6, and IL-11 by mononuclear cells of patients with refractory anemia. Cytokine 2002 Nov 24; 20 (4): 154-62
14. Zinzar S, Silverman LR, Richardson EB, et al. Azacytidine plus verapamil induces the differentiation of a newly characterized biphenotypic human myeloid-B lymphoid leukemic cell line BW-90. Leuk Res 1998 Aug; 22 (8): 677-85
15. Marcucci G, Silverman L, Eller M, et al. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 2005 May; 45 (5): 597-602
16. Pharmion Corporation. Product information (US): Vidaza™ (azacitidine for injectable suspension) 100mg [online]. Available from URL: http://www.pharmion.com [Accessed 2005 Aug 1]
17. New drug application (no. 050794): Vidaza (azacitidine) injectable suspension; submitted to the US Food and Drug Administration by Pharmion Corporation [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/ 50-794_Vidaza.-htm [Accessed 2005 Aug 1]
18. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodys-plastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002 May 15; 20 (10): 2429-40
19. Silverman LR, Holland JF, Demakos EP, et al. Azacitidine (Aza C) in myelodysplastic syndromes (MDS), CALBG studies 8421 and 8921 [abstract no. 46]. Ann Hematol 1994; 68: A12
20. Gryn J, Zeigler ZR, Shadduck RK, et al. Treatment of myelodysplastic syndromes with 5-azacytidine. Leuk Res 2002 Oct; 26 (10): 893-7
21. Jani CR, Pechet L, Ballen KK, et al. 5-Azacytidine treatment of patients with myelodysplastic syndrome results in resolution of red cell transfusion dependence for some patients, and for one patient with transformed AML (t-AML), elimination of marrow blasts for nearly two years [abstract no. 4823]. Blood 2001 Nov 16; 98 (11 Pt 2): 272b
22. Koldehoff M, Westerhausen M. 5-Azacytidine treatment for recurrent myelodysplastic syndromes and secondary acute myeloblastic leukemias [abstract no. 432P]. Ann Oncol 2000; 11 Suppl. 4: 96-7
23. Powell BL, Loeser CS, Lyerly ES, et al. Azacytidine treatment for recurrent myelodysplastic syndromes after induction therapy for acute myeloid leukemia [abstract no. 4049]. Blood 1997 Nov 15; 90 Suppl. 1 Pt 2: 289b
24. Rugo H, Damon L, Ries C, et al. Treatment of myelodysplastic syndromes (MDS) with subcutaneous 5-azacytidine (Aza C) [abstract no. 1254]. Blood 1994 Nov 15; 84 Suppl. 1: 317
25. Kornblith AB, Herndon IIJE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodys-plastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002 May 15; 20 (10): 2441-52